CN Patent
CN113015531A — 用于皮下施用的药物调配物
Assigned to AbbVie Inc · Expires 2021-06-22 · 5y expired
What this patent protects
本公开涉及重量比为约20:1的左旋多巴4'‑单磷酸酯和卡比多巴4'‑单磷酸酯的组合物以及通过皮下施用此类组合物治疗帕金森氏病和相关病状的方法。
USPTO Abstract
本公开涉及重量比为约20:1的左旋多巴4'‑单磷酸酯和卡比多巴4'‑单磷酸酯的组合物以及通过皮下施用此类组合物治疗帕金森氏病和相关病状的方法。
Drugs covered by this patent
- foscarbidopa (FOSCARBIDOPA) · AbbVie GK
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.